253 related articles for article (PubMed ID: 17362385)
1. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
Barua A; Bradaric MJ; Kebede T; Espionosa S; Edassery SL; Bitterman P; Rotmensch J; Luborsky JL
Am J Reprod Immunol; 2007 Apr; 57(4):243-9. PubMed ID: 17362385
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor antibodies in ovarian cancer.
Luborsky JL; Barua A; Shatavi SV; Kebede T; Abramowicz J; Rotmensch J
Am J Reprod Immunol; 2005 Aug; 54(2):55-62. PubMed ID: 16105096
[TBL] [Abstract][Full Text] [Related]
3. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
4. Anti-ovarian antibodies in sera of patients with ovarian tumors.
Szubert S; Michalak S; Szpurek D; Moszynski R; Krygowska-Zielinska J; Sajdak S
Immunol Lett; 2012 Dec; 148(2):133-7. PubMed ID: 23026238
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients.
Chinni SR; Falchetto R; Gercel-Taylor C; Shabanowitz J; Hunt DF; Taylor DD
Clin Cancer Res; 1997 Sep; 3(9):1557-64. PubMed ID: 9815843
[TBL] [Abstract][Full Text] [Related]
6. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
Gadducci A; Ferdeghini M; Buttitta F; Fanucchi A; Annicchiarico C; Prontera C; Bevilacqua G; Genazzani AR
Anticancer Res; 1996; 16(6B):3519-23. PubMed ID: 9042215
[TBL] [Abstract][Full Text] [Related]
8. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Genazzani AR
Anticancer Res; 1998; 18(5B):3763-5. PubMed ID: 9854491
[TBL] [Abstract][Full Text] [Related]
9. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
[TBL] [Abstract][Full Text] [Related]
10. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
[TBL] [Abstract][Full Text] [Related]
11. [Autoantibodies to steroid-producing ovarian cells in cancer patients].
Bershteĭn LM; Poroshina TE; Vasil'ev DA; Orlova AV
Vopr Onkol; 2008; 54(5):602-5. PubMed ID: 19069474
[TBL] [Abstract][Full Text] [Related]
12. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
Taylor DD; Lyons KS; Gerçel-Taylor C
Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
[TBL] [Abstract][Full Text] [Related]
13. [Serological analysis of antibodies by anti-idiotypic monoclonal antibody 6B11 against ovarian carcinoma].
Feng J; Lü J; Qian H
Zhonghua Fu Chan Ke Za Zhi; 1996 Aug; 31(8):493-5. PubMed ID: 9275445
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer.
Kim S; Cho H; Nam EJ; Kim SW; Kim YT; Park YW; Kim BW; Kim JH
Genes Chromosomes Cancer; 2010 Jul; 49(7):585-95. PubMed ID: 20461751
[TBL] [Abstract][Full Text] [Related]
15. Induction of immune responses to ovarian tumor antigens by multiparity.
Shields LB; Gerçel-Taylor C; Yashar CM; Wan TC; Katsanis WA; Spinnato JA; Taylor DD
J Soc Gynecol Investig; 1997; 4(6):298-304. PubMed ID: 9408885
[TBL] [Abstract][Full Text] [Related]
16. [Clinical importance of serum anti-p53 antibodies as tumor markers].
Sakai H; Okamoto E
Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
[TBL] [Abstract][Full Text] [Related]
17. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
18. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer.
Gerçel-Taylor C; Bazzett LB; Taylor DD
Gynecol Oncol; 2001 Apr; 81(1):71-6. PubMed ID: 11277653
[TBL] [Abstract][Full Text] [Related]
19. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers.
Korneeva I; Bongiovanni AM; Girotra M; Caputo TA; Witkin SS
Am J Obstet Gynecol; 2000 Jul; 183(1):18-21. PubMed ID: 10920302
[TBL] [Abstract][Full Text] [Related]
20. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
